Objective: We sought to model the feasibility of a simultaneous in field boost (SIB) to individual brain metastases during a course of whole brain radiotherapy (WBXRT) using helical tomotherapy (HT) intensity-modulated radiation therapy. Patients and Methods: Planning computed tomography data from 14 patients with 1 to 3 brain metastases were used to model an intralesional SIB delivery that yielded a total intralesional dose of 60 Gy with a surrounding whole brain dose of 30 Gy (designed to be isoeffective to WBXRT of 30 Gy with an 18 Gy in 1 fraction radiosurgery boost). Accuracy of treatment of a phantom on the HT unit was measured. Comparisons of HT delivery versus a conventional stereotactic radiotherapy technique for a particularly challenging simulated anatomy were made. Results: In all cases, SIB to 60 Gy with WBXRT to 30 Gy was possible while maintaining critical structures below assigned dose limits. Estimated radiation delivery time for the SIB treatment was approximately 10 minutes per fraction. Planning and treatment of the head phantom was associated with an overall accuracy of 2 mm. Comparison to conventional noncoplanar arc fractionated stereotactic radiotherapy plan demonstrated similar target coverage and improved critical tissue sparing even for a challenging anatomy with multiple lesions in the same plane as the optic apparatus. Conclusions: Based on this study, use of an image guided SIB using HT seemed feasible and a phase I trial initiated at our institution is described. Potential advantages of this approach include frameless stereotaxis through daily megavoltage computed tomography localization, more efficient use of resources and exploitation of radiobiologic advantages of fractionation.
B rain metastases are a common cancer problem and the results with current treatments are generally unsatisfactory. The majority of patients with brain metastases are treated with whole brain radiotherapy (WBXRT). Clinical trials have suggested selected subgroups of patients (ie, younger age, good performance status, extracranial metastases absent or controlled, single metastasis) may benefit from more aggressive local treatment of their intracranial disease with surgery or radiosurgery with or without WBXRT. 1, 2 Helical tomotherapy combines intensity modulated fanbeam radiotherapy delivery with megavoltage computed tomography (MVCT) imaging for patient positioning. 3 Such a combination provides a potential alternative to conventional stereotactic frame systems for precision radiotherapy. 4 Comparisons of serial or helical tomotherapy delivery for primary and metastatic brain tumors suggests comparable normal tissue sparing and target coverage compared with other precision radiotherapy techniques. [5] [6] [7] [8] Tomotherapy lends itself to synchronous boost strategies as multiple targets can be easily treated to different dose levels in the course of the rotational delivery. Thus, tomotherapy could potentially allow radiosurgery type boost treatments to be given synchronously with the WBXRT component and could be used to efficiently boost multiple brain metastases without the need for separate stereotactic procedures. In this study, we model the feasibility of helical tomotherapy to deliver a synchronous boost with WBXRT to achieve intralesional biologically effective doses (BED) similar to single fraction stereotactic radiosurgery. We also describe preliminary data of a phase I trial of this approach underway at our institution.
PATIENTS AND METHODS
Selection of the dose and fractionation prescription for the helical tomotherapy (HT) simultaneous in field boost (SIB) technique was based on previously reported experience with single fraction radiosurgery alone or combined with WBXRT for treatment of patients with oligometastatic disease to brain. In our calculations we assumed a ␣/␤ of 10 for tumor and 3 for late effects using the linear quadratic formulation to convert single fraction doses into the fractionated SIB scheme. Within the RTOG 90-05 radiosurgery dose escalation protocol 9 metastases in the 3-to 4-cm range were treated with a radiosurgery dose up to 15 to 18 Gy (depending on lesion size) without toxicity, while smaller lesions were treated with doses up to 24 Gy without toxicity. Within the RTOG 9508 trial, 10 radiosurgery boosts of between 15 to 20 Gy were used in addition to a whole brain dose of 37.5 Gy in 15 fractions for a total lesion BED of 159 to 222 Gy. Using the synchronous boost technique, we calculated that a total intralesion dose of 60 Gy in 10 fractions delivered with a surrounding whole brain dose of 30 Gy in 10 fractions would provide a similar BED to a radiosurgery boost of 18 Gy in 1 fraction combined with WBXRT to 30 Gy in 10 fractions. In the RTOG 9005 and 9508, radiosurgery boost dose was assigned based on lesion size and a volume-toxicity association is well recognized when single fraction radiosurgery techniques are used. Because of the fractionated nature of the SIB technique we chose to use an SIB dose isoeffective to a midrange radiosurgery boost dose (18 Gy in 1 fraction) without adjustment for lesion size. In the phase I trial described below, patient enrolment is restricted to those patients with lesion size 3 cm or less. This upper limit to lesion size ensures that our choice of an 18 Gy equivalent fractionated SIB dose will still be appropriate (ie, equal to or less than the corresponding single fraction radiosurgery dose as used in the RTOG 9005 and 9805) within the range of lesion sizes being treated.
Understanding that the beam penumbra and lower dose regions around the SIB boost volumes differ from conventional radiosurgery approaches we also sought to establish reference points for comparison to our SIB plans. This is somewhat challenging as most dosimetric comparisons of radiosurgery techniques consider only the radiosurgery boost volume itself and do not factor into account the effect of the whole brain dose "wash" produced when combining radiosurgery as a boost after WBXRT. Podgorsak et al 11 published a dosimetric comparison of radiosurgery techniques using a range of photon beam energies and arc arrangements. Assuming a 1-cm lesion was to be encompassed by the 90% isodose (the prescription isodose), significant differences in the radiosurgical dose profile were noted between radiosurgical techniques at 5 to 15 mm from the target. For instance, at 5 mm from the target, dose ranged from 10% to 40% (median 25%); at 10 mm Ͻ5% to 25% (median 15%) and at 15 mm Ͻ5% to 20% (median 10%). Assuming a dose of 18 Gy prescribed to the 90% isodose lines, these doses would correspond to BEDs of 13, 6, and 3 Gy at 5, 10, and 15 mm from the target. Added to the BED of 69 Gy (37.5 Gy in 15 fractions) from the whole brain component as per the RTOG 9508, total BED to the brain surrounding the focal target of 82, 75, and 72 Gy at 5, 10, and 15 mm, respectively. This would correspond to doses of 37 Gy (at 5 mm), 35 Gy (at 10 mm), and 34 Gy (at 15 mm) given in 10 fractions. These estimates were used as checks for the peri-lesional dose distribution for the SIB plans (although they were not explicitly specified as dose planning constraints). Likewise, a maximum dose of 35 Gy in 10 fractions for brainstem and chiasm in the SIB treatment was estimated assuming a tolerance of 50 Gy in 25 fractions and this dose was used as a dose constraint for these critical structures in the inverse planning. Treatment planning constraints specified for the inversely planned HT SIB technique described in our study are outlined in Table 1 .
Planning computed tomography (kVCT) scan data (acquired with 3 mm slice thickness) from 6 patients with brain metastases previously treated with fractionated stereotactic radiotherapy at our institution were replanned with these target doses using the helical tomotherapy planning system (Hi•ART II, Tomotherapy Inc., Madison, WI). These cases were planned to establish dosimetric feasibility of the approach before initiating a phase I dose escalation trial of this technique. We also generated plans at the 60 Gy dose level for 8 patients who were subsequently enrolled on lower dose levels (35-50 Gy) of a phase I dose escalation trial of this approach. To compare the tomotherapy SIB technique to a conventional stereotactic radiotherapy delivery, we generated an additional planning study using a clinical CT data set with 3 simulated lesions including 2 of lesions in the same axial plane at the level of the eyes and optic chiasm. This anatomy was specifically chosen to detect if there was a relative disadvantage to coplanar helical tomotherapy versus noncoplanar stereotactic radiotherapy delivery. Thus, we generated a total of 15 HT SIB plans based on clinical CT planning data plus one conventional stereotactic radiotherapy plan.
Planning parameters 12 used for the tomotherapy plans were fan beam thickness: 2.5 or 5.0 cm; pitch: 0.3 to 0.4; modulation factor: 3.0; normal calculation grid (1.8 ϫ 1.8 ϫ 3 mm 3 ). Target and normal tissue constraints used for planning are listed in Table 1 . For optimization and reporting purposes, maximum doses to organs were specified as maximum dose to a minimum, but still clinically significant volume. For example, maximum dose to whole brain was specified as maximum dose to a minimum volume of 1% of the total brain volume (D1). By specifying a minimum volume, spurious results because of isolated dose peaks within clinically insignificant volumes (such as a single calculation voxel) were avoided. For the conventional stereotactic radiotherapy, a plan with WBXRT to 30 Gy followed by a sequential stereotactic radiotherapy boost of 30 Gy in 10 fractions to the 3 lesions using conventional noncoplanar arc arrangements (6 arcs per isocenter, 5 mm MLC leaf collimation per arc) was generated using a commercial stereotactic radiotherapy planning system (X-knife, Integra Radionics, MA). To verify treatment accuracy, an anthropomorphic (Rando) phantom was used to simulate delivery of SIB treatment of 2 intracerebral brain metastases (1 temporal tip, 1 parietal) to verify accuracy of treatment. The head phantom was initially scanned on the kVCT scanner and critical structures and targets contoured. The same constraints as the clinical cases were used for planning. A pretreatment MVCT scan (6-mm slice thickness) was performed and coregistration with the planning kVCT was performed to align the head phantom for treatment. Internal gold grain fiducial markers were used to estimate the accuracy of the positioning registration. Treatment was then performed and the resulting delivery verified with film dosimetry.
RESULTS

Feasibility Study
The 6 cases planned to establish clinical feasibility included a variety of lesion locations including temporal tip locations where close proximity adjacent globe, optic nerve, brainstem, and chiasm created challenging organ at risk sparing scenarios. In all cases it was possible to plan prescription doses to the individual lesions to the maximum dose of 60 Gy while keeping critical structures within clinically acceptable dose limits. In particular dose to lens and optic nerves were within clinically acceptable limits despite the coplanar rotational delivery. Estimated treatment time for the clinical feasibility cases ranged from 9 minutes to 11 minutes. As the total treatment time is mainly determined by the need to deliver 30 Gy to a large volume, it is nearly independent of the boost dose.
In-Phantom Verification and Comparison to Convention SRT
For the phantom treatment, an overall registration accuracy in the superior or inferior direction of 2 mm or better (1 mm in axial plane accuracy) was found when we correlated the actual internal fiducial marker position with the results of the automated registration algorithm. The measured dose distribution using film dosimetry showed excellent agreement with the calculated dose distribution (less than 5% difference). Overall treatment time for the head phantom was 10 minutes for a delivered intralesion dose of 60 Gy. For the 3 lesion phantom study, dose escalation to 30 Gy whole brain with 60 Gy SIB to individual lesions was possible despite the fact that 2 of the lesions planned were in the same plane.
Comparison of dose volume histograms demonstrated comparable target coverage and normal tissue sparing versus a conventional multiarc stereotactic radiotherapy boost added to WBXRT (Table 2 and Figs. 1 and 2 ). It should be noted that the 30 Gy boost planned for the traditional arc SRT plan here would need to be delivered in a fractionated fashion to maintain biologic equivalence to the HT plan and render comparison of the dose volume histogram (DVH) curves legitimate. In practice, single fraction radiosurgery boosts are typically used when multiple arc delivery is planned and calculation of BED adjusted DVH curves for comparison with single fraction plans are necessary. Such BED adjusted curves would tend to exaggerate any differences in normal tissue DVH curves because of the high dependence of critical structures on larger fraction size (low ␣/␤ ratio), thus, the differences noted in this comparison (in favor of HT) are likely a conservative estimate of the actual difference between the 2 techniques.
Phase I Clinical Study
On the basis of these results we commenced an Research Ethics Board approved phase I dose escalation trial using tomotherapy to deliver WBXRT to 30 Gy with an escalating synchronous boost to individual lesions to doses between 35 and 60 Gy. All patients have a contrast enhanced planning CT or CT fused with a contrast enhanced magnetic resonance imaging (MRI) for planning purposes. The individual contrast enhancing lesions are contoured as the SIB targets without margin and the whole cranial contents with a 3-mm 3D margin contoured as the target for the whole-brain treatment. Patients are treated using conventional thermoplastic mask immobilization with positioning based on coregistration of the planning kVCT and an MVCT acquired immediately before treatment. Patients treated on the trial must have tomotherapy plans generated that meet assigned organ at risk dose constraints and be verified in phantom with film dosimetry before treatment. Toxicity is monitored weekly during treatment and every 6 weeks post-treatment. Response on imaging at 12 weeks post-treatment is assessed. Patients are accrued at 3 to 6 patients per dose level and escalation to the next dose level occurs if no limiting (grade 3 or greater) toxicity is observed in more than 1 of 3 or 2 of 6 patients by 3 months post-treatment. This end point was designed to be similar to the initial dose RTOG radiosurgery escalation studies. 9 Patients will also be monitored for long-term toxicity, understanding that the treatment paradigm being explored is novel and that important central nervous system toxicity endpoints, such as radionecrosis may manifest after the initial 3-month observation point. Careful correlation of these toxicity endpoints with treatment parameters such as SIB dose, number of lesions treated and lesion sizes treated will be necessary to ensure appropriate application of the MTD determined in our phase I trial to future patients. This correlation will be especially important given the novel nature of the prescription and delivery scheme, which differs from traditional single fraction radiosurgery boost paradigms.
Average patient treatment time on trial has been 459 seconds (range, 278 -604 seconds) and is influenced by the fan beam width chosen for delivery (2.5 cm versus 5 cm). Average vector positioning correction has been 1.8 mm (range, 1.5-2.5 mm). Excellent correlation between planned treatments and in phantom verification on the HT unit has been noted. To date, no limiting acute or subacute toxicity attributable to the treatment has been observed and currently we are accruing to the 50 Gy dose level. As indicated in Table  1 , plans generated at the 60 Gy target for the first 8 patients treated on trial at lower dose levels also met target and normal tissue constraints. The majority of patients have had stable disease or partial responses when assessed 3 months posttreatment.
Including all the cases in Table 2 , minimum dose to whole brain was 29.7 Gy (29. 4 -30) and maximum dose to brain (excluding lesions) was 32.2 (30.8 -34.5). Intralesional doses averaged a maximum of 62.6 Gy (61-66.5) and a minimum of 59.2 Gy (57.5-60.5). Planning constraints for some of the organs at risk were more demanding than clinically acceptable doses to drive the plan optimization in the needed direction. In all cases, dose to critical structures were below accepted clinical tolerances for these structures: chiasm maximum dose 32.4 Gy (27.8 -37.4), brainstem 32.3 Gy (30 -35), right lens 5.1 Gy (3.6 -6.1), left lens 5.2 Gy (4.3-6.2), right optic nerve 22.2 Gy (17-34.5), and left optic nerve 22.8 Gy (18 -32) . For comparison to a conventional fractionation scheme, the maximum dose noted to a critical structure was 37.4 Gy in 10 fractions to the chiasm in the second phantom or clinically simulated case study (P2 in Table 2 ) and this equates to a dose of 50 Gy in 25 fractions (assuming ␣/␤ ϭ 3), within accepted tolerance for this structure. It should be noted that this study was deliberately constructed to be a challenging case, with 2 lesions requiring SIB located in the same plane as the optic apparatus (eyes, nerve, chiasm). These data suggest the ultimate target dose level of 60 Gy is dosimetrically feasible and potential toxicity will be the main consideration in dose escalation using this novel scheme rather than technical delivery of the boost dose.
DISCUSSION
An integrated fractionated boost would reduce the number of treatment sessions (reducing patient inconvenience) especially as multiple lesions need to be boosted. For example, Amendola described treating up to 10 lesions per patients over multiple with gamma knife radiosurgery sessions 13 although most investigators would not recommend focal treatment (radiosurgery or surgery) for patients with more than 1 to 3 lesions and WBXRT alone for palliation would typically be used. 2 Randomized studies demonstrating benefit of radiosurgery for brain metastases have typically included patients with up to 3 metastases. 10, 14 As noted in our work the treatment time with the tomotherapy SIB is relatively independent of the number of lesions being boosted and may be a feasible strategy for treating multiple intracranial lesions efficiently. Both radiosurgery and the tomotherapy SIB techniques possess advantages over surgery in terms of the ability to treat multiple lesions at one session without the need for multiple craniotomies. Clearly, there is a point where treating multiple intracranial lesions aggressively is inappropriate and WBXRT alone or supportive care only is the more appropriate option. In our phase I trial, we are restricting enrollment to those patients with adequate performance status, systemic disease that is controlled or absent and with 3 or fewer brain metastases.
The tomotherapy SIB strategy also exploits the potential benefits of fractionation including the effects of reassortment of tumor cells into sensitive phases of the cell cycle and the reoxygenation of hypoxic areas of the tumor. Hall et al 15 have argued that fractionated stereotactic radiotherapy may be more efficacious in the treatment of neoplastic disease compared with single fraction radiosurgery. The integrated boost also keeps overall treatment courses short to minimize tumor cell repopulation and patient inconvenience. A potential downside of this approach is removing the potential normal tissue recovery time afforded by an interval between the WBXRT treatment and the radiosurgery boost. Whether the potential advantages of reducing overall treatment time on tumor control will be outweighed by an increase in toxicity because of less opportunity for normal tissue repair remains to be seen and hopefully will be reflected in the results of the phase I trial currently underway.
Current stereotactic radiosurgery and stereotactic radiotherapy practice requires rigid patient immobilization through either invasive stereotactic frames or elaborate relocatable frame systems. 4 Beam delivery with conventional linear accelerators requires the use of special circular or micromultileaf collimators to deliver multiple noncoplanar arcs or static beams. Helical tomotherapy provides a potential integrated solution to a number of these requirements. 3, 16 Coregistration of MVCT with planning kVCT allows precision patient localization without elaborate immobilization. Chase et al using MVCT to reposition patients on a HT device noted an interfraction position variation (1 SD) of approximately 2 mm. 17 We noted a similar accuracy in our phantom study where registration accuracy of 1 mm within plane of reconstruction and 2 mm between MVCT slices in fine resolution (1 SD) was noted. Treatment on our phase I protocol has revealed daily positioning corrections similar to Chase et al (average vector positioning correction of 1.8 mm). Other authors using traditional single fraction radiosurgery 18 have noted improved local control and no increase in toxicity with the routine addition of a 1 mm CTV margin to the contrast enhancing margin of the lesions targeted for the radiosurgery boost. These findings suggest the 1 to 2 mm accuracy afforded by our noninvasive, MVCT guided localization, combined with our fractionated prescription should be safe, even if the noninvasive localization is slightly less than the submillimeter precision of invasive frame systems. Both serial and helical tomotherapy approaches incorporate rotational intensity modulated fan beam delivery as an alternative to static conformal or arc based delivery. In a discussion of linear accelerator delivery techniques using fixed circular collimators, Podgorsak et al noted improved conformity for noncoplanar delivery compared with single plane rotational delivery 11 suggesting tomotherapy approaches should be at a disadvantage compared with conventional stereotactic techniques. In tomotherapy, however, the ability to modulate the beam intensity from multiple (51 in the case of HT) coplanar projections helps offset the disadvantage of coplanar delivery. Another potential limitation is the width of the fan beam delivery. In serial tomotherapy, fan beam widths are approximately 2 cm (although a tertiary collimator device exists to generate finer fan beam widths 19 ). In helical tomotherapy, fan beam widths of 2.5 cm or greater are typically used, however, the use of smaller couch pitch for delivery (amount of couch movement per rotation) effectively increases the "resolution" of the fan beam delivery in the superior or inferior direction. In addition, strategies for "sharpening" the beam in the longitudinal axis have been described. 20 In comparisons of serial tomotherapy to gamma knife delivery 5 and helical tomotherapy to conventional photon and proton stereotactic techniques, 7, 8, 21 tomotherapy has been demonstrated to provide comparable conformity with excellent target dose homogeneity. These studies also demonstrate that tomotherapy generates somewhat larger lower isodose volumes compared with noncoplanar and proton techniques. The clinical relevance of differences at these low isodose levels remains to be determined as normal tissue constraints and normal tissue complication probabilities were not dramatically different between the modalities compared in these studies. 7, 8, 21 Thus, tomotherapy would appear to be a feasible alternative for precision radiotherapy to small intracranial volumes.
While we did not generate conventional noncoplanar stereotactic radiotherapy plans for all our cases, our test comparison for a deliberately constructed challenging anatomy suggested there might not be a significant disadvantage to the coplanar delivery of HT even in situations of multiple lesions in the same anatomic plane when combined with WBXRT. In the particular case studied, the tomotherapy SIB technique was superior in terms of the ability to spare brainstem, lens and optic nerves compared with multiple arc stereotactic radiotherapy (SRT) although chiasm sparing was somewhat better with SRT. The ability to incorporate boost contributions to larger field lower dose volumes as part of the optimization process is an advantage of the simultaneous boost strategy. 22 In the case of the treatment of brain metastases using the SIB technique the limitations of coplanar delivery associated with tomotherapy may be offset by the ability to incorporate the lower isodose "spill" as a component contributing to the whole brain radiation dose. Finally, while our strategy has been to exploit the ability of tomotherapy to simultaneously boost individual brain lesions, conformal avoidance with intensity modulated radiotherapy techniques like tomotherapy is equally feasible. This strategy has been proposed as a method to reduce potential morbidity of WBXRT by the avoidance of sensitive structures such as the hippocampus.
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CONCLUSION
We have confirmed the feasibility of using helical tomotherapy to deliver a radiosurgery type boost synchronously with WBXRT in planning and phantom studies. We are examining the clinical feasibility of this approach in a phase I clinical trial currently in progress where the target dose is 30 Gy WBXRT (over 10 fractions) with a concurrent boost to individual lesions with an additional 30 Gy to a total dose of 60 Gy (in 10 fractions).
